Uncategorized
Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2017, along with a general business update. Aerie Highlights RhopressaTM (netarsudil ophthalmic solution) 0.02% remains on track after a success